Chronic Lymphocytic Leukemia Clinical Trial

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Summary

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults ≥18 years of age
Patient has a life expectancy ≥ 3 month

Patient has relapsed or refractory disease Relapsed lymphoma: Relapsed lymphoma is disease that has responded to treatment but then returns.

Refractory lymphoma: Failure to achieve complete response at the end of therapy or progression within 6 months from completion of therapy

Included Diseases

DLBCL, including transformed lymphoma
Mantle Cell Lymphoma
PTCL
CTCL
leukemia-cll/" >CLL/SLL
Follicular lymphoma
Marginal zone lymphoma
Hodgkin lymphoma (both classical and lymphocyte predominant)
Waldenströms Macroglobulinemia
Must has failed or is not a candidate for available therapies with reasonable likelihood of clinical benefit, which includes FDA approved products and standard of care regimens
Therapy means at least three front lines of therapy including Hematopoeitic Stem Cell Transplant (HSCT and/or Chimeric Antigen Receptor (CAR) T cells, when applicable
Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study
Males must agree to use an adequate method of contraception during the study
Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2

Adequate hepatic and renal functions as defined by:

Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and
Total bilirubin ≤1.5 times ULN; and

Estimated glomerular filtration rate (eGFR) of at least 50ml/min. These estimations can be calculated using the following methods:

Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation
Cockcroft Gault equation
Modification of Diet in Renal Disease (MDRD study equation)
Creatinine clearance estimated by 24-hr urine collection for creatinine clearance
Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
Willing and able to provide written informed consent

Exclusion Criteria:

Active non-hematologic malignancy other than lymphoid malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed
Known, active Central Nervous System (CNS) involvement of disease requiring intrathecal therapy. Note: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
Patient eligible for high dose chemotherapy and autologous stem cell transplant
Indolent non-Hodgkin lymphoma (iNHL)

Patients at high risk of Tumor Lysis Syndrome (TLS)

a. Bulky disease i. A unidimensional lesion greater than 10 cm and/or b. Lymphocyte count greater than 25,000 per µL

Receipt of any anti-cancer therapy within 14 days prior to Cycle 1 Day 1 (C1D1)
Uncontrolled active, untreated, or progressive infection
Receipt of any investigational agent or on study treatment within 30 days prior to C1D1
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
Active hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on Hepatitis C Virus (HCV) positive antibody [HCV Ab]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody)
Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline EKG abnormality (e.g., QTcF >470 msec)
Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
Uncontrolled seizure disorder
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason.

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT04072458

Recruitment Status:

Recruiting

Sponsor:

Bio-Path Holdings, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Georgia Cancer Center
Augusta Georgia, 30912, United States More Info
Julie Stiefel
Contact
706-721-0734
[email protected]
Locke J Bryan, MD
Principal Investigator
Sarah Cannon Research Institute/Tennesee Oncology
Nashville Tennessee, 37203, United States
MD Anderson Cancer Research Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT04072458

Recruitment Status:

Recruiting

Sponsor:


Bio-Path Holdings, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.